Stphane Bancel, CEO of Moderan, hopes to publish the interim results of his clinical trial of the Covid-19 vaccine in November and the United States could authorize emergency use in December, as it progresses today The Wall Street Journal.
Bancel has pointed out during the annual Tech Live conference organized by this newspaper that it is possible that the vaccine will not be definitively approved until next year, although the first preliminary results of definitive permission from the US Government that it is possible that the government’s permission to use the vaccine will not arrive until next year, although the first efficacy analysis, which will be carried out on 53 people, will be carried out next month, although the manager cannot specify more dates as it is difficult to predict, Reuters reports.
In statements prior to Financial Times, Moderna’s CEO had set the date of November 25 as the earliest to be able to talk about results, but starting to produce it on a large scale once the first efficacy analyzes are obtained is also a challenge. “If one of the ingredients is not available, we cannot manufacture it,” he told WSJ.
Moderna plans to produce 20 million doses of its experimental vaccine by the end of the year, according to the pharmaceutical laboratory last month, and has a base of 25,296 participants in the clinical trial of the 30,000 planned for phase III, the last one.
The pharmaceutical industry is participating in a race against time to develop an effective vaccine with Covid-19, with more than 150 potential candidates, among which, in addition to Moderna, Pfiser and AstraZeneca stand out as more feasible options.